Cara Therapeutics(US:CARA)2025-11-13 21:14Financial Performance - Net loss for Q3 2025 was $5.5 million, roughly flat compared to the net loss of $5.5 million in Q3 2024, with a net loss per share of $0.59[9] - Cash, cash equivalents, and short-term investments as of September 30, 2025, were $36.5 million, an increase from $31.6 million as of December 31, 2024, with a cash runway anticipated to last into Q4 2026[10] - The balance sheet shows total assets of $39.0 million as of September 30, 2025, compared to $35.2 million as of December 31, 2024[17] Research and Development - Research and development expenses for Q3 2025 were $3.6 million, down from $4.8 million in Q3 2024, primarily due to lower costs associated with TTI-101 trials[7] - The company reported a decrease in expenses related to TTI-101 trials, with a $1.4 million reduction in HCC trial costs and a $1.0 million reduction in IPF trial costs[7] - Topline data from the Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) is expected in H1 2026[1] - Results from a healthy volunteer study of the next-generation STAT3 inhibitor, TTI-109, are also anticipated in H1 2026[1] - The Phase 2 REVERT IPF trial did not meet its goals, prompting further analysis to determine next steps[6] Operating Expenses - General and administrative expenses increased to $2.3 million in Q3 2025 from $0.9 million in Q3 2024, driven by higher professional fees and personnel costs[8] Strategic Focus - The company is focused on advancing its therapeutic potential in fibrosis-driven diseases through ongoing clinical trials[3]